ArticleThe Journal of investigative dermatology2015
Unfolding the mutational landscape of human melanoma.
Article in The Journal of investigative dermatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- PLA1A expression as a diagnostic marker of BRAF-mutant metastasis in melanoma cancer.Scientific reports · 2021Trial
- Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies.Journal for immunotherapy of cancer · 2020Trial
- Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.The Journal of clinical investigation · 2018Trial
- Dermokine mutations contribute to epithelial-mesenchymal transition and advanced melanoma through ERK/MAPK pathways.PloS one · 2023Article
- Immunotherapy in Advanced Prostate Cancer: Current Knowledge and Future Directions.Biomedicines · 2022Review
- Unbiased High-Throughput Drug Combination Pilot Screening Identifies Synergistic Drug Combinations Effective against Patient-Derived and Drug-Resistant Melanoma Cell Lines.SLAS discovery : advancing life sciences R & D · 2021Article
- Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer.Cancers · 2021Review
- Synthetic lethality of a cell-penetrating anti-RAD51 antibody in PTEN-deficient melanoma and glioma cells.Oncotarget · 2019Article
- Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.NPJ genomic medicine · 2017Article
- Pediatric melanoma: incidence, treatment, and prognosis.Pediatric health, medicine and therapeutics · 2017Review
- Challenging the standard of care in advanced melanoma: focus on pembrolizumab.Cancer management and research · 2017Review
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
Abstract
Over the preceding two decades, sophisticated sequencing techniques have been used to characterize the genetic drivers of adult melanoma. However, our understanding of pediatric melanomas is still rudimentary. In this report, we comment on a thorough multi-platform analysis of common pediatric melanoma subsets, including pediatric conventional melanoma (CM), congenital nevus-derived melanoma (CNM), and Spitzoid melanoma (SM), contributed by Lu et al.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.